ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 664,56
-0,41%
Dow Jones
39 285,45
-0,06%
DAX
18 452,41
0,00%
Brent Oil
87,46
0,15%
Bitcoin
55 730,54
-2,19%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Freeline Therapeutics Holdings PLC (FRLN)

  7. Freeline Therapeutics Holdings PLC (FRLN) Actualités

FRLN

Freeline Therapeutics (FRLN)

Freeline Therapeutics Holdings PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FRLN
DateHeureSourceTitreSymboleSociété
24/04/202422h00GlobeNewswire Inc.Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:FRLNFreeline Therapeutics Holdings PLC
26/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/02/202422h38Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/02/202422h28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:FRLNFreeline Therapeutics Holdings PLC
20/02/202421h22Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
20/02/202413h13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:FRLNFreeline Therapeutics Holdings PLC
20/02/202413h00GlobeNewswire Inc.Acquisition of Freeline by Syncona Becomes EffectiveNASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/02/202418h00GlobeNewswire Inc.Freeline Shareholders Approve Acquisition by SynconaNASDAQ:FRLNFreeline Therapeutics Holdings PLC
08/12/202323h21Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/11/202313h30GlobeNewswire Inc.Syncona to Acquire Freeline TherapeuticsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
25/10/202308h01GlobeNewswire Inc.Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressNASDAQ:FRLNFreeline Therapeutics Holdings PLC
16/10/202313h00GlobeNewswire Inc.Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressNASDAQ:FRLNFreeline Therapeutics Holdings PLC
04/10/202313h00GlobeNewswire Inc.Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
15/08/202313h00GlobeNewswire Inc.Freeline Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
08/08/202313h30GlobeNewswire Inc.Freeline Therapeutics to Host Second Quarter 2023 Financial Results CallNASDAQ:FRLNFreeline Therapeutics Holdings PLC
31/07/202313h30GlobeNewswire Inc.Freeline to Participate in Upcoming Investor ConferencesNASDAQ:FRLNFreeline Therapeutics Holdings PLC
25/07/202313h30GlobeNewswire Inc.Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
26/06/202313h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:FRLNFreeline Therapeutics Holdings PLC
26/06/202313h30GlobeNewswire Inc.Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
02/06/202314h00GlobeNewswire Inc.Freeline to Present at 2023 Jefferies Healthcare ConferenceNASDAQ:FRLNFreeline Therapeutics Holdings PLC
30/05/202313h30GlobeNewswire Inc.Freeline Reports First Quarter 2023 Financial Results and Business HighlightsNASDAQ:FRLNFreeline Therapeutics Holdings PLC
22/05/202314h00GlobeNewswire Inc.Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher DiseaseNASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/05/202314h05GlobeNewswire Inc.Freeline Completes ADS Ratio ChangeNASDAQ:FRLNFreeline Therapeutics Holdings PLC
21/04/202314h54Edgar (US Regulatory)Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)NASDAQ:FRLNFreeline Therapeutics Holdings PLC
21/04/202313h00GlobeNewswire Inc.Freeline Announces Proposed ADS Ratio ChangeNASDAQ:FRLNFreeline Therapeutics Holdings PLC
12/04/202314h00GlobeNewswire Inc.Freeline to Present at 22nd Annual Needham Virtual Healthcare ConferenceNASDAQ:FRLNFreeline Therapeutics Holdings PLC
04/04/202313h03Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:FRLNFreeline Therapeutics Holdings PLC
04/04/202313h00GlobeNewswire Inc.Freeline Reports Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:FRLNFreeline Therapeutics Holdings PLC
28/03/202313h00GlobeNewswire Inc.Freeline Therapeutics to Host Full Year 2022 Financial Results CallNASDAQ:FRLNFreeline Therapeutics Holdings PLC
14/02/202319h55Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FRLNFreeline Therapeutics Holdings PLC
 Showing the most relevant articles for your search:NASDAQ:FRLN

Dernières Valeurs Consultées

EU
DG
Vinci
NYSE
NKE
Nike
NASDAQ
NVDA
NVIDIA
EU
CS
Axa
FTSE
UKX
FTSE 100
EU
BN
Danone
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
NASDAQ
AMZN
Amazon.com
EU
PX1
CAC 40
EU
PX4
SBF 120
EU
GLE
Societe Generale
EU
BEL20
Bel 20
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés